newsfilter
← Latest News
Business Wire·

Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

R&D Day highlighted TRACTr, TRACIr, and ARM pipeline progress and best-in-class potential of novel bispecific ARM platform for autoimmune diseases Enrollment ongoing for JANX007 and JANX008 Updates on JANX007